Ablynx: Corporate Presentation (Ablynx) - Nov 14, 2014 - "ALX-0061 - compelling Phase IIa results in RA patients"; "Treatment was highly efficacious and was well tolerated at all doses"; "No increase of adverse events upon extension of treatment"; "No anti-drugs antibodies were reported"
P2a data • Rheumatoid Arthritis
|